Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

1.8K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.8K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

4.2K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
4.2K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

726
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
726
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.1K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

4.1K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Black phosphorus nanomaterials induce hepatic lipid metabolism disorders by triggering oxidative stress and mitochondrial dysfunction.

Particle and fibre toxicology·2026
Same author

Empowerment model construction and empirical study of community-based recruitment of platelet donors.

Frontiers in public health·2026
Same author

Comparative repair efficacy of three mesenchymal stem cell sources in rat full-thickness talar cartilage defects.

Scientific reports·2026
Same author

Non-antibiotic drug-induced microbiotoxicity as a pharmacological variable.

Chemico-biological interactions·2026
Same author

Corrigendum to "Single-cell RNA sequencing reveals depot-specific characteristics of adipose progenitor cells in ducks" [Poultry Science, Volume 105/Issue 7, July 2026, 107004].

Poultry science·2026
Same author

Fear of progression and associated factors in glaucoma patients: a latent profile analysis.

BMC psychology·2026

Related Experiment Video

Updated: Jan 15, 2026

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

11.5K

Targeting Multiple Pathophysiological Axes in COPD: Nanomaterial Advances.

Qianyue Zhang1, Shuanglan Xu2, Chunyan Yang3

  • 1Kunming Medical University, Kunming, Yunnan, 650500, People's Republic of China.

International Journal of Nanomedicine
|October 8, 2025
PubMed
Summary

This review identifies nano-intervention targets for chronic obstructive pulmonary disease (COPD) by examining its core pathophysiology. It explores nanocarrier systems to improve drug delivery and overcome current therapeutic challenges.

Keywords:
COPDdrug deliverynanocarriersnanomaterialtargeted therapy

More Related Videos

Author Spotlight: Development and Characterization of an In Vitro Model to Study Chronic Cigarette Smoke Exposure and Its Impact on Airway Epithelial Cells in COPD Research
09:07

Author Spotlight: Development and Characterization of an In Vitro Model to Study Chronic Cigarette Smoke Exposure and Its Impact on Airway Epithelial Cells in COPD Research

Published on: July 12, 2024

1.8K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.4K

Related Experiment Videos

Last Updated: Jan 15, 2026

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

11.5K
Author Spotlight: Development and Characterization of an In Vitro Model to Study Chronic Cigarette Smoke Exposure and Its Impact on Airway Epithelial Cells in COPD Research
09:07

Author Spotlight: Development and Characterization of an In Vitro Model to Study Chronic Cigarette Smoke Exposure and Its Impact on Airway Epithelial Cells in COPD Research

Published on: July 12, 2024

1.8K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.4K

Area of Science:

  • Nanomedicine
  • Pulmonary Medicine
  • Biotechnology

Background:

  • Chronic obstructive pulmonary disease (COPD) presents significant global health challenges due to progressive nature and limited treatment efficacy.
  • Current COPD therapies suffer from poor drug bioavailability in the lungs and off-target systemic toxicity.
  • Addressing these limitations requires novel therapeutic strategies targeting COPD's complex pathophysiology.

Purpose of the Study:

  • To systematically identify and analyze nano-intervention targets specific to COPD pathophysiology.
  • To critically evaluate existing respiratory-adaptive nanocarrier systems for COPD treatment.
  • To provide a roadmap for advancing nano-interventions towards precision therapeutics for COPD.

Main Methods:

  • Systematic identification of COPD-specific nano-intervention targets across four pathophysiological axes: inflammation, redox imbalance, protease-antiprotease homeostasis, and airway remodeling.
  • Critical evaluation of nanocarrier systems like polymer nanoparticles (PLGA-PEG) and lipid nanoparticles (LNPs).
  • Review of existing literature on nanoparticle efficacy, targeting efficiency, and biocompatibility in pulmonary delivery.

Main Results:

  • Identified key nano-intervention targets within COPD's core pathophysiological mechanisms.
  • Demonstrated enhanced neutrophil targeting efficiency (6.5-fold) with PLGA-PEG nanoparticles (*p* < 0.001).
  • Achieved >90% siRNA-mediated inflammatory gene suppression using lipid nanoparticles (LNPs).
  • Highlighted biocompatibility concerns, such as silica nanoparticles increasing TGF-β (1.8-fold, *p* < 0.05).

Conclusions:

  • Nano-interventions hold promise for improving COPD treatment by enhancing pulmonary drug delivery and reducing systemic toxicity.
  • Challenges in nanoparticle engineering, pulmonary biocompatibility, and regulatory hurdles must be addressed for clinical translation.
  • Future research should focus on stimulus-responsive platforms, multidisease targeting, and AI-driven personalized formulations for advanced COPD nanotherapeutics.